Synergy Pharmaceuticals Inc. Raises $200M Rule 144A Offering of 7.50% Convertible Senior Notes

Sichenzia Ross Friedman Ference LLP Represents Synergy Pharmaceuticals Inc. in $200M Rule 144A Offering of 7.50% Convertible Senior Notes

New York, NY – (Global Newswire, November 5, 2014) – New York based securities and corporate law firm Sichenzia Ross Friedman Ference LLP announced that it  represented Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), a biopharmaceutical developer of drugs to treat gastrointestinal disorders and diseases, in a Rule 144A offering of $200 million of 7.50% Convertible Senior notes. The notes are convertibles into shares of Synergy Pharmaceutical’s common stock at a conversion price of approximately $3.11 per share.

The SRFF team was led by Partner Jeffrey J. Fessler.

[starbox id=1]